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The Intra-aortic Balloon Pump (IABP) is currently the most
commonly used mechanical assist device to improve and support
hemodynamics in patients with cardiogenic shock; it is widely used
also in high-risk patients undergoing percutaneous coronary inter-
vention (PCI) or coronary artery bypass grafting (CABG) [1–9].
However, the impact of IABP on prognosis is so far controversial [5,10].
We assessed the in-hospital mortality and complications in
patients treated with IABP consecutively admitted to our Intensive
Cardiac Care Unit (ICCU).
From Jan. 1, 2005 to Dec. 31, 2008, 3500 patients were consecutively
admitted to our ICCU [11–13]. Among them, 414 (11.8%) underwent IABP
during their hospitalization and were prospectively enrolled in our
Registry.
Large ischemic risk area (LIRA)was defined as “ejection fraction less
than 40% together with proximal occlusion of left descending anterior
coronary artery associated or not with critical lesions in other
coronary arteries”. In these patients IABP was deployed after PCI.
Patients were defined as “high risk” as if one ormore of the following
criteria were present: ventricular ejection fraction (LVEF)<40%, killip
class 3, persistent malignant ventricular arrhythmias, acute mitral
regurgitation and severe coronary artery disease (left main stem or
three vessel or vein graft disease).
Major bleeding.Major bleeding was defined according to Replace 2
[14]:
Continuous data (Kolmogorov–Smirnov test ) were expressed as
mean±SD, categorical data as frequencies and percentages. All data
were analysed by means of Fisher's exact test or Student's t test, when
appropriate. Variables resulted significantly different between sub-
groups were entered as covariates in a backward stepwise logistic
regression analysis. A p<0.05 was considered statistical significant
(SPSS 13.0 statistical software; SPSS Inc., Chicago, ILL, USA).
The mean age of patients in the study was 68.5±11.4 years; 69.6%
were men. Hypertension was detectable in 51.4% (n=213), dyslipi-
demia in 32.1% (n=133) and diabetes mellitus in 22.0% (n=91).
About one fourth of patients (24.4%) showed prior myocardial
infarction and prior PCI in the 20.5%.
Table 1 shows indications for IABP in our series. In the majority of
patients (67.1%, n=278) IABP was the only device, while in the
remaining (32.9%) it was associated to other devices. The device most
frequently associated with IABP was mechanical ventilation (41.7%;
invasive: 24.6%; non-invasive 17.1%). The continuous veno-venous
renal replacement therapy was used in 13.5% (n=56) of patients.
Unfractioned heparin was used in 97.8% of patients. The majority of
patients received dual antiplatelet therapy; acetylsalicylic acid
(90.6%) and clopidogrel (83.8%). Therapy with glycoprotein IIb IIIa
inhibitors was administered in 59.7% of cases. Inotropic agents
(epinephrine, norepinephrine, dopamine and dobutamine) were
used in 40.6% of patients, all with refractory cardiogenic shock.
In our series, complications were 13.8% (57/414 patients) (Table 2).
Thirtypatients (outof 57, 52.7.%) showed severebleeding, amongwhich
half of patients exhibited unknown bleeding site while bleeding at the
insertion site occurred in 12 patients. The incidence of IABP-related
complications did not differ betweenmales and females (10.6%@versus
13.9% p=0.398). Patients who developed IABP-related complications
showed a higher median duration of the device (48 h; 25–75th
percentile 24–72 hversus 36 h;25–75thpercentile 24–48 h;p=0.007).
In our population, 82 patients died (82/414:19.8%). Among patients
who died, IABP was implanted because of: cardiogenic shock in 59
patients (72%), cardiac arrest in 8 patients (9.8%), periprocedural
complications of PCI in 5 patients (6.1%), mechanical complication of
acute myocardial infarction in 4 patients (4.9%), large ischemic risk area
in 3 patients (3.6%), acute pulmonary edema in 2 patients (2.4%) and
bridge to CABG in 1 patient (1.2%).
Among the 47 patientswhodeveloped IABP-related complications 22
died; two deaths were due to IABP (intestinal ischemia in 1 patients and
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Large ischemic risk area 86 (34.3)
Cardiogenic shock 73 (29.1)
Hypotension 38 (15.1)
Sudden death/VF 15 (6.0)
In the caht lab 4 (26.7)
Outside the cath lab 11 (73.3)
PCI failure 14 (5.6)
Acute pulmonary edema 11 (4.4)
Mechanical complications 10 (4.0)
Mitral regurgitation 6
VSD 4
Peri-procedural complications 2 (0.8)
Pre-operative support 2 (0.8)
STEMI [latency>12 h]
(n=38 [9.2%])
Cardiogenic shock 16 (42.1)
Large ischemic risk area 7 (18.4)









disease in high-risk patients
28 (25.7)
Hypotension 20 (18.3)
Cardiogenic shock 16 (14.7)
Peri-procedural complications 15 (13.8)
Acute pulmonary edema 12 (11.0)
Pre-operative support 10 (9.2)
Sudden death/VF 8 (7.3)
In the caht lab 4
Outside the cath lab 4
CHD with CABG
indication (n=9 [2.2%])
Election procedure 3 (33.3)
Cardiogenic shock 3 (33.3)
Refractory angina 2 (22.2)




Cardiogenic shock 5 (100.0)
STEMI: ST elevation myocardial infarction; VF: ventricular fibrillation; PCI:
percutaneous coronary intervention; UA: unstable angina; NSTEMI: non ST elevation
myocardial infarction; VSD: ventricular septal defect; CHD: coronary heart disease.




Strictly related to IABP Severe bleeding 30 (52.7%)
Non specific site (acute anemia) 15 (50.0%)
Bleeding at the insertion site 12 (40.0%)
Retro-peritoneal hematoma 3 (10.0)




Pseudo aneurysm of femoral artery 3 (5.3%)
Not strictly related to
IABP
Gastrointestinal and urinary bleeding 10 (17.5%)
severe bleeding associated with retroperitoneal hematoma in 1 patient).
In ourpopulationoverall strictly IABP-relatedmortalitywas0.5% (2/414).
At backward logistic regression analysis the following variableswere
independent predictors for in-ICCUmortality: killip class (OR 1.86; 95%
CI 1.41–2.46; p<0.001); age (OR 1.04; 95%CI 1.01–1.08; p=0.018);
aPTT max (OR 1.007; 95%CI 1.001–1.013; p=0.015); eGFR (OR 0.98;
95%CI 0.96–0.99; p=0.037) and admission glycemia (OR 2.07; 95%CI
1.39–3.07; p<0.001). Hosmer–Lemeshow test: 2.996; p=0.935.
At backward logistic regression analysis the following variables
resulted as independent predictor for IABP-related complications
(when adjusted for age and admission systolic blood pressure, and
IABP duration): aPTT max (OR 1.008; 95%CI 1.002–1.013; p=0.010);
admission glycemia (OR 1.68; 95%CI 1.21–2.34; p=0.002); minimum
platelet count (OR 0.991; 95%CI 0.985–0.997; p=0.005). Hosmer–
Lemeshow test: 8.23; p=0.412.
The main findings of our Registry are as follows: a) in our clinical
practice the most frequent indications for IABP implantation are not
included in guidelines; b) the incidence of “strictly IABP-related”
mortality and complications are low and c) clinicians should carefully
monitor anticoagulation, since aPTT max is an independent predictor
for IABP-related complications.
In our institution, the most frequent indication for IABP implanta-
tion is represented by large ischemic risk area in STEMI patients
treated with primary PCI. So far, this indication is supportedmainly by
experimental data [15,16]. In a randomized experimental study,
Azevedo et al. [16] demonstrated that IABP counterpulsation improves
the time course of recovery of LV systolic function after reperfused
AMI. Using both tagged and contrast enhanced magnetic resonance
imaging, the Authors demonstrated that this beneficial effect is mainly
due to an acceleration of the functional recovery of non-infarcted,
stunnedmyocardial regions. A series of 116 subjects at a single center,
following successful PCI for anterior AMI and total occlusion received
either conventional treatment or an IABP. Those subjectswhohad IABP
after successful PTCA had lower rates of reinfarction (0/48) with
respect to patientswithout IABP 1/42 [17]. In our investigation, though
our study design does not allowus to drawany conclusions in regard to
benefits (since the lack of randomization), IABP implantation in
patients with large ischemic risk area is safe since the incidence of
complications in this subgroup is low as well as its mortality.
The most frequent and feared complication is represented by
major bleeding and aPTT max resulted an independent predictor for
IABP-related complications, thus underlining the importance of a
close monitoring of anticoagulation in these patients.
In our series, the incidence of IABP-related complications is higher
than that reported in the Benchmark Registry [3], mainly because of
the different definitions of severe bleeding and different inclusion
criteria for complication. [18–20].
In our daily current practice, indications for IABP implantation are
not strictly those reported in guidelines. However IABP can be
considered a safe device because of the low incidence of IABP-related
complications and mortality.
The authors of this manuscript have certified that they comply
with the Principles of Ethical Publishing in the International Journal of
Cardiology [21].
References
[1] Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving
outcomes. Circulation 2008;117(5):686–97.
[2] Trost JC, Hillis DL. Intra-aortic balloon counterpulsation. Am J Cardiol 2006;97:
1391–8.
[3] Ferguson III JJ, CohenM, Freedman RJ, Stone GW,Miller MF, Joseph DL, Ohman EM.
The current practice of intra aortic balloon counterpulsation: results from the
Benchmark Registry. J Am Coll Cardiol 2001;38:1456–62.
[4] Cohen M, Urban P, Christenson JT, et al. Intra aortic balloon counterpulsation in US
andnon-UScentres: results of theBenchmarkRegistry. EurHeart J 2003;24:1763–70.
[5] Sjauw KD, Engström AE, Vis MM, et al. A systematic review and meta-analysis of
intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should
we change the guidelines? Eur Heart J 2009;30(4):459–68.
[6] Sjauw KD, Engstrom AE, Henriques JP. Percutaneous mechanical cardiac assist in
myocardial infarction. Where are we now, where are we going? Acute Card Care
2007;9:222–30.
[7] Brodie BR, Stuckey TD, Hansen C, Muncy D. Intra-aortic balloon counterpulsation
before primary percutaneous transluminal coronary angioplasty reduces cathe-
terization laboratory events in high-risk patients with acute myocardial infarction.
Am J Cardiol 1999;84:18–23.
[8] Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the
management of patients with ST-elevation myocardial infarction: a report of the
American College of Cardiology/American Heart Association Task Force on Practice
Guidelines (Committee to Revise the 1999 Guidelines for the Management of
Patients with Acute Myocardial Infarction). Circulation 2004;110:e82–e292.
[9] Kushner FG, HandM, Smith Jr SC, et al. 2009 focused updates: ACC/AHA guidelines for
the management of patients with ST elevation myocardial infarction (updating the
2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on
percutaneous coronary intervention (updating the 2005 guideline and 2007 focused
update) a report of the American College of Cardiology Foundation/American Heart
AssociationTask ForceonPracticeGuidelines. J AmColl Cardiol 2009;54(23):2205–41.
[10] Stone GW, Marsalese D, Brodie BR, et al. A prospective, randomized evaluation of
prophylactic intraaortic balloon counterpulsation in high risk patients with acute
myocardial infarction treated with primary angioplasty. JACC 1997;29(7):1459–67.
[11] Valente S, Lazzeri C, Sori A, Giglioli C, Bernardo P, Gensini GF. The recent evolution
of coronary care units into intensive cardiac care units: the experience of a tertiary
center in Florence. J Cardiovasc Med (Hagerstown) 2007;8(3):181–7.
[12] Valente S, Lazzeri C, Chiostri M, Sori A, Giglioli C, Salvadori C, Gensini GF. Time of
onset and outcome of cardiogenic shock in acute coronary syndrome. J Cardiovasc
Med (Hagerstown) 2008;9(12):1235–40.
[13] Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal
myocardial infarction in acute coronary syndrome patients receiving coronary
stenting are predicted by residual platelet reactivity to ADP detected by a point-of-
care assay: a 12 month follow-up. Circulation 2009;119(2):237–42.
[14] Feit F, Voeltz MD, Attubato MJ, et al. Predictors and impact of major hemorrhage
on mortality following percutaneous coronary intervention from the REPLACE-2
Trial. Am J Cardiol 2007;100(9):1364–9.
[15] Achour H, Boccalandro F, Felli P, Amirian J, Uthman M, Buja M, Smalling RW.
Mechanical left ventricular unloading prior to reperfusion reduces infarct size in a
canine infarction model. Catheter Cardiovasc Interv 2005;64(2):182–92.
[16] Azevedo CF, Amado LC, Kraitchman DL, et al. The effect of intra-aortic balloon
counterpulsation on left ventricular functional recovery early after acute
myocardial infarction: a randomized experimental magnetic resonance imaging
study. Eur Heart J 2005;26:1235–41.
[17] Ishihara M, Sato H, Tateishi H, Uchida T, Dote K. Intraaortic balloon pumping as the
postangioplasty strategy in acutemyocardial infarction. AmHeart J 1991;122(2):385–9.
[18] Cheng JM, Valk SDA, den Uil CA, et al. Usefulness of intra-aortic balloon pump
counterpulsation in patients with cardiogenic shock from acute myocardial
infarction. Am J Cardiol 2009;104:327–32.
[19] Chen EW, Canto JG, Parsons LS, et al. Relation between hospital intra-aortic
balloon counterpulsation volume and mortality in acute myocardial infarction
complicated by cardiogenic shock. Circulation 2003;108:951–7.
[20] Azeem T, Stephens-Lloyd A, Spyt T, Hartshorne R, Gershlick AH. Intra-aortic
balloon counterpulsation: variations in use and complications. Int J Cardiol 2004;94:
255–9.
[21] Coats AJ. Ethical authorship and publishing. Int J Cardiol 2009;131:149–50.
0167-5273/$ – see front matter © 2010 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.ijcard.2010.10.044
239Letters to the Editor
